- Home
- ORMP vs AGEN Comparison
ORMP vs AGEN Comparison
Compare ORMP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- AGEN
- Stock Information
- Founded
- ORMP 2002
- AGEN 1994
- Country
- ORMP United States
- AGEN United States
- Employees
- ORMP N/A
- AGEN N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORMP Health Care
- AGEN Health Care
- Exchange
- ORMP Nasdaq
- AGEN Nasdaq
- Market Cap
- ORMP 104.6M
- AGEN 123.6M
- IPO Year
- ORMP N/A
- AGEN 2000
- Fundamental
- Price
- ORMP $2.21
- AGEN $3.94
- Analyst Decision
- ORMP
- AGEN Buy
- Analyst Count
- ORMP 0
- AGEN 2
- Target Price
- ORMP N/A
- AGEN $14.50
- AVG Volume (30 Days)
- ORMP 135.0K
- AGEN 457.8K
- Earning Date
- ORMP 11-07-2025
- AGEN 11-10-2025
- Dividend Yield
- ORMP N/A
- AGEN N/A
- EPS Growth
- ORMP N/A
- AGEN N/A
- EPS
- ORMP N/A
- AGEN N/A
- Revenue
- ORMP $2,000,000.00
- AGEN $101,706,000.00
- Revenue This Year
- ORMP N/A
- AGEN $60.49
- Revenue Next Year
- ORMP N/A
- AGEN N/A
- P/E Ratio
- ORMP N/A
- AGEN N/A
- Revenue Growth
- ORMP N/A
- AGEN N/A
- 52 Week Low
- ORMP $1.82
- AGEN $1.38
- 52 Week High
- ORMP $3.09
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- ORMP 38.97
- AGEN 45.45
- Support Level
- ORMP $2.30
- AGEN $3.63
- Resistance Level
- ORMP $2.40
- AGEN $4.11
- Average True Range (ATR)
- ORMP 0.11
- AGEN 0.21
- MACD
- ORMP -0.02
- AGEN -0.00
- Stochastic Oscillator
- ORMP 33.33
- AGEN 33.73
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).